الفهرس 
Grave’s diseaseOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Background: Grave’s disease is an autoimmune disorder affecting the thyroid gland, characterized by the presence of circulating autoantibodies that bind to and stimulate the thyroid-stimulating hormone receptor (TRAb), resulting in hyperthyroidism and goiter. GD may also cause extrathyroidal manifestations as; Grave’s ophthalmopathy, Grave’s dermopathy and acropachy.
Selenium is an essential trace element, it has a vital role in the maintenance of endocrinal functions, immunity, metabolism, and cellular homeostasis. The thyroid gland, compared to other body organs, has the highest concentration of selenium, indicating the crucial role of selenium for thyroid physiology. Selenium deficiency may be important in the start and progress of autoimmune thyroid diseases in genetically predisposed individuals. Besides, cell‐mediated and the humoral immune response may be impaired in selenium deficiency.
Objectives: evaluate the selenium status by measuring serum selenoprotein P (SEPP) level in GD patients, in comparison to healthy subjects and assess the linkage between selenium status and Grave’s ophthalmopathy (GO).
Patients and Methods: A case control study that was conducted on 80 subjects; group (A): 40 patients diagnosed with GD and group (B): 40 control subjects at Endocrinology clinic at Ain Shams university hospitals in the period between December 2020 and June 2021. All the included GD patients suffered from GO.
Results: Selenoprotein P levels “as a marker of selenium status” were significantly lower in GD patients than control subjects. No significant correlation was found between selenium status and GO severity and selenium status.
Conclusion: GD patients are markedly selenium deficient. GO activity and severity were not correlated to selenium status. Free T4 can be used for prediction of selenoprotein p level which increased by 1.32 in each unit Free T4 increase.